Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
September 26, 2024 06:00 ET
|
Centessa Pharmaceuticals plc
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological,...
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
September 12, 2024 22:34 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
September 11, 2024 16:04 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
September 10, 2024 07:00 ET
|
Centessa Pharmaceuticals plc
2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)Favorable safety and tolerability profile with no observations...
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
August 27, 2024 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly...
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 21, 2024 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
August 13, 2024 07:00 ET
|
Centessa Pharmaceuticals plc
Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data...
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
June 10, 2024 07:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 21, 2024 08:45 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
May 13, 2024 16:10 ET
|
Centessa Pharmaceuticals plc
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexin Agonist Program: Cleared IND...